Related references
Note: Only part of the references are listed.Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
Anders Lindholm Sorensen et al.
HAEMATOLOGICA (2020)
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study
Alessandro Rambaldi et al.
LEUKEMIA (2020)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
New Perspectives on Polycythemia Vera: From Diagnosis to Therapy
Alessandra Iurlo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
Joan How et al.
CANCERS (2020)
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis
Alberto Ferrari et al.
HAEMATOLOGICA (2019)
Oral idasanutlin in patients with polycythemia vera
John Mascarenhas et al.
BLOOD (2019)
A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline
Mary Frances McMullin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes
Shashank Cingam et al.
JOURNAL OF BLOOD MEDICINE (2019)
Updates in the management of polycythemia vera and essential thrombocythemia
Prithvirai Bose et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial
Martin Griesshammer et al.
ANNALS OF HEMATOLOGY (2018)
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
Ruben Mesa et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
Emmanuelle Verger et al.
BLOOD CANCER JOURNAL (2018)
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Alberto Alvarez-Larran et al.
HAEMATOLOGICA (2017)
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Alberto Alvarez-Larran et al.
HAEMATOLOGICA (2017)
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials
Tiziano Barbui et al.
HAEMATOLOGICA (2017)
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
Srdan Verstovsek et al.
LEUKEMIA RESEARCH (2017)
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials
Tiziano Barbui et al.
HAEMATOLOGICA (2017)
What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?
Alessandro M. Vannucchi et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
Alessandro Maria Vannucchi et al.
ANNALS OF HEMATOLOGY (2017)
Myeloproliferative neoplasms: A decade of discoveries and treatment advances
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms
Prithviraj Bose et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia
Gunnar Birgegard
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea
Alberto Alvarez-Larran et al.
ANNALS OF HEMATOLOGY (2014)
The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells
Min Lu et al.
BLOOD (2014)
A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea
Srdan Verstovsek et al.
CANCER (2014)
Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation
Bin-Tao Huang et al.
LEUKEMIA RESEARCH (2014)
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
Guido Finazzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug
Emil T. Kuriakose et al.
HAEMATOLOGICA (2013)
Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha
Thomas Stauffer Larsen et al.
LEUKEMIA RESEARCH (2013)
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
Elisabetta Antonioli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
Alberto Alvarez-Larran et al.
BLOOD (2012)
Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells
Min Lu et al.
BLOOD (2012)
Roles of p53 in Various Biological Aspects of Hematopoietic Stem Cells
Takenobu Nii et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2012)
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
Alessandro Rambaldi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs
Nina Saban et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission
Thomas Stauffer Larsen et al.
HEMATOLOGY (2009)
Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms
J-J Kiladjian et al.
LEUKEMIA (2008)
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
V. Guerini et al.
LEUKEMIA (2008)
Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage
Y. Hong et al.
LEUKEMIA (2006)
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status:: a prospective study
PJ Campbell et al.
LANCET (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
